Published in J Mater Sci Mater Med on April 01, 2002
Crystallization modifies osteoconductivity in an apatite-mullite glass-ceramic. J Mater Sci Mater Med (2003) 1.08
The role of Sr2+ on the structure and reactivity of SrO-CaO-ZnO-SiO2 ionomer glasses. J Mater Sci Mater Med (2007) 0.97
Effect of strontium-containing hydroxyapatite bone cement on bone remodeling following hip replacement. J Mater Sci Mater Med (2010) 0.84
The optimum zinc content in set calcium phosphate cement for promoting bone formation in vivo. Mater Sci Eng C Mater Biol Appl (2009) 0.82
Porous allograft bone scaffolds: doping with strontium. PLoS One (2013) 0.75
Strontium ions substitution in brushite crystals: the role of strontium chloride. J Funct Biomater (2011) 0.75
The Feasibility and Functional Performance of Ternary Borate-Filled Hydrophilic Bone Cements: Targeting Therapeutic Release Thresholds for Strontium. J Funct Biomater (2017) 0.75
Effect of fluoride treatment on the fracture rate in postmenopausal women with osteoporosis. N Engl J Med (1990) 5.49
Stimulatory effect of zinc on bone formation in tissue culture. Biochem Pharmacol (1987) 1.12
Zinc is a potent inhibitor of osteoclastic bone resorption in vitro. J Bone Miner Res (1995) 1.09
The nature of the injury to the calcifying mechanism in rickets due to strontium. Biochem J (1935) 1.03
Skeletal effects of zinc deficiency in growing rats. J Trace Elem Med Biol (1999) 1.00
The biocompatibility of glass-poly(alkenoate) (Glass-Ionomer) cements: a review. J Biomater Sci Polym Ed (1991) 0.92
Ionos bone cement (glass-ionomer): an experimental and clinical evaluation in joint replacement. Clin Mater (1990) 0.87
Effects of low doses of strontium on bone quality and quantity in rats. Bone (1990) 0.87
Effect of low doses of stable strontium on bone metabolism in rats. Miner Electrolyte Metab (1985) 0.86
Ionomeric bone cement in neuro-otological surgery. J Laryngol Otol (1992) 0.85
The effects of fluoride therapy on metabolic bone disease. A histologic study. Clin Orthop Relat Res (1968) 0.84
Ionomer-based bone substitute in otologic surgery. Eur Arch Otorhinolaryngol (1993) 0.83
Strontium inhibition of vitamin D3-induced calcium-binding protein (CaBP) and calcium absorption in chick intestine. Proc Soc Exp Biol Med (1970) 0.81
Effects of strontium on calcium metabolism in rats. II. Strontium prevents the increased rate of bone turnover in ovariectomized rats. Jpn J Pharmacol (1995) 0.80
A comparison of the effects of strontium chloride and calcium chloride on alveolar bone. Calcif Tissue Int (1983) 0.77
Acute zinc deficiency and trabecular bone loss in rats with talc granulomatosis. Biol Trace Elem Res (1991) 0.75
Potent effect of zinc acexamate on bone components in the femoral-metaphyseal tissues of elderly female rats. Gen Pharmacol (1998) 0.75
Distinct mechanism for antidepressant activity by blockade of central substance P receptors. Science (1998) 2.83
Differential distribution of 5HT1D- and 5HT1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia (1997) 1.99
A method for comparing the potencies of -aminobutyric acid antagonists on single cortical neurones using micro-iontophoretic techniques. Br J Pharmacol (1973) 1.82
Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein. Neuropharmacology (1999) 1.60
Aetiology and incidence of facial fractures in adults. Int J Oral Surg (1983) 1.49
Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacology (1999) 1.48
A comparative study of some convulsant substances as gamma-aminobutyric acid antagonists in the feline cerebral cortex. Br J Pharmacol (1973) 1.45
Targeted disruption of a B2 bradykinin receptor gene in mice eliminates bradykinin action in smooth muscle and neurons. J Biol Chem (1995) 1.40
A technique allowing e.e.g. and activity recording together with intraventricular administration of drugs in the conscious rabbit. Br J Pharmacol (1973) 1.39
Endogenous opioids and pain: a review. J R Soc Med (1981) 1.38
Bicyclic phosphorus esters that are potent convulsants and GABA antagonists. Nature (1976) 1.37
Antagonism of GABA by picrotoxin in the feline cerebral cortex. Br J Pharmacol (1972) 1.37
Pharmacology of a selective cyclooxygenase-2 inhibitor, L-745,337: a novel nonsteroidal anti-inflammatory agent with an ulcerogenic sparing effect in rat and nonhuman primate stomach. J Pharmacol Exp Ther (1995) 1.37
Evaluation of bicuculline as a GABA antagonist. Nature (1971) 1.35
Evidence that bicuculline can both potentiate and antagonize GABA. Br J Pharmacol (1971) 1.34
Convulsive properties of d-tubocurarine and cortical inhibition. Nature (1972) 1.25
Rat hippocampal slices 'in vitro' display spontaneous epileptiform activity following long-term organotypic culture. J Neurosci Methods (1989) 1.24
kappa-Opioid agonists produce antinociception after i.v. and i.c.v. but not intrathecal administration in the rat. Br J Pharmacol (1988) 1.23
Effects of cholecystokinin and related peptides on neuronal activity in the ventromedial nucleus of the rat hypothalamus. Br J Pharmacol (1988) 1.19
Characterisation of the ultrastructure of glass-ionomer (poly-alkenoate) cement. Br Dent J (1992) 1.19
Effects of a focal penicillin lesion on responses of rabbit cortical neurones to putative neurotransmitters. Br J Pharmacol (1972) 1.19
Neurokinin-receptor antagonists: pharmacological tools and therapeutic drugs. Can J Physiol Pharmacol (1997) 1.16
Neurotransmitter candidates of somatosensory primary afferent fibres. Neuroscience (1983) 1.15
Intravital microscope studies on the effects of neurokinin agonists and calcitonin gene-related peptide on dural vessel diameter in the anaesthetized rat. Cephalalgia (1997) 1.15
Fracture toughness of acrylic denture base. Biomaterials (1983) 1.13
Tachykinin NK1 receptor antagonists act centrally to inhibit emesis induced by the chemotherapeutic agent cisplatin in ferrets. Neuropharmacology (1996) 1.12
Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat--intravital microscope studies. Cephalalgia (1997) 1.12
The non-peptide neurokinin1 receptor antagonist, RP 67580, blocks neurogenic plasma extravasation in the dura mater of rats. Br J Pharmacol (1993) 1.10
Expression of B1 and B2 bradykinin receptor mRNA and their functional roles in sympathetic ganglia and sensory dorsal root ganglia neurones from wild-type and B2 receptor knockout mice. Neuropharmacology (1997) 1.08
Crystallization modifies osteoconductivity in an apatite-mullite glass-ceramic. J Mater Sci Mater Med (2003) 1.08
Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in Dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats. Neuropharmacology (1995) 1.05
The novel NK1 receptor antagonist MK-0869 (L-754,030) and its water soluble phosphoryl prodrug, L-758,298, inhibit acute and delayed cisplatin-induced emesis in ferrets. Neuropharmacology (2000) 1.04
Proceedings: Presynaptic inhibition and the depressant actions of GABA and glycine in the feline cuneate nucleus: changes related to electrographic seizure activity. J Physiol (1973) 1.02
Plus and minus-bicuculline methochloride as optical isomers of a GABA antagonist. Nature (1974) 1.01
Amino acid antagonists and the depression of cuneate neurones by -aminobutyric acid (GABA) and glycine. Br J Pharmacol (1973) 1.01
The novel anti-migraine agent rizatriptan inhibits neurogenic dural vasodilation and extravasation. Eur J Pharmacol (1997) 1.01
Microiontophoretic release of drugs from micropipettes: use of 24Na as a model. Br J Pharmacol (1973) 1.01
Tissue-engineered oral mucosa. J Dent Res (2012) 1.00
Actions of the GABAB agonist, (-)-baclofen, on neurones in deep dorsal horn of the rat spinal cord in vitro. Br J Pharmacol (1989) 1.00
Antagonism of gamma-aminobutyric acid and glycine by convulsants in the cuneate nucleus of cat. Br J Pharmacol (1976) 1.00
Tissue-engineered oral mucosa: a review of the scientific literature. J Dent Res (2007) 1.00
Excitation of single sensory neurones in the rat caudal trigeminal nucleus by iontophoretically applied adenosine 5'-triphosphate. Neurosci Lett (1983) 1.00
Cloning, characterization and central nervous system distribution of receptor activity modifying proteins in the rat. Eur J Neurosci (2001) 1.00
A preliminary comparison of the mechanical properties of chemically cured and ultrasonically cured glass ionomer cements, using nano-indentation techniques. Biomaterials (2001) 1.00
Influence of sodium oxide content on bioactive glass properties. J Mater Sci Mater Med (1999) 1.00
Effects of the bradykinin B1 receptor antagonist des-Arg9[Leu8]bradykinin and genetic disruption of the B2 receptor on nociception in rats and mice. Pain (1997) 0.99
Enantioselective inhibition of apomorphine-induced emesis in the ferret by the neurokinin1 receptor antagonist CP-99,994. Neuropharmacology (1994) 0.99
Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation. Br J Clin Pharmacol (1999) 0.99
Antagonism by folic acid of presynaptic inhibition in the rat cuneate nucleus. Br J Pharmacol (1974) 0.99
Pharmacological profile of PD 117302, a selective kappa-opioid agonist. Br J Pharmacol (1987) 0.98
The cholecystokinin receptor antagonist L364,718 increases food intake in the rat by attenuation of the action of endogenous cholecystokinin. Br J Pharmacol (1988) 0.98
In vivo evidence for spinal delta-opiate receptor operated antinociception. Neuropeptides (1986) 0.97
Differential effects of the 5HT1B/1D receptor agonist naratriptan on trigeminal versus spinal nociceptive responses. Cephalalgia (1998) 0.97
Rizatriptan has central antinociceptive effects against durally evoked responses. Eur J Pharmacol (1997) 0.96
L-733,060, a novel tachykinin NK1 receptor antagonist; effects in [Ca2+]i mobilisation, cardiovascular and dural extravasation assays. Eur J Pharmacol (1996) 0.96
PD117302: a selective agonist for the kappa-opioid receptor. Br J Pharmacol (1988) 0.96
Effects of the delta-opioid receptor antagonist naltrindole on antinociceptive responses to selective delta-agonists in post-weanling rats. Br J Pharmacol (1992) 0.96
Role of exchanged ions in the integration of ionomeric (glass polyalkenoate) bone substitutes. Biomaterials (1997) 0.95
The effect of phosphate content on the bioactivity of soda-lime-phosphosilicate glasses. J Mater Sci Mater Med (2009) 0.95
Role of opioid receptors in neurogenic dural vasodilation and sensitization of trigeminal neurones in anaesthetized rats. Br J Pharmacol (2001) 0.94
Dural vasodilation causes a sensitization of rat caudal trigeminal neurones in vivo that is blocked by a 5-HT1B/1D agonist. Br J Pharmacol (1999) 0.94
Proceedings: Some neuropharmacological properties of the new non-barbiturate hypnotic etomidate (R (+)-ethyl-1-(alpha-methyl-benzyl) imidazole-5-carboxylate). Br J Pharmacol (1975) 0.94
Effect of RP 67580, a non-peptide neurokinin1 receptor antagonist, on facilitation of a nociceptive spinal flexion reflex in the rat. Br J Pharmacol (1993) 0.94
Kappa opioid receptor activation depresses excitatory synaptic input to rat locus coeruleus neurons in vitro. Neuroscience (1987) 0.93
Antinociceptive activity of NK1 receptor antagonists: non-specific effects of racemic RP67580. Br J Pharmacol (1993) 0.93
Region selective up-regulation of micro-, delta- and kappa-opioid receptors but not opioid receptor-like 1 receptors in the brains of enkephalin and dynorphin knockout mice. Neuroscience (2003) 0.93
Comparison of the vasoconstrictor effects of rizatriptan and sumatriptan in human isolated cranial arteries: immunohistological demonstration of the involvement of 5-HT1B-receptors. Br J Clin Pharmacol (1998) 0.93
An immunocytochemical investigation of human trigeminal nucleus caudalis: CGRP, substance P and 5-HT1D-receptor immunoreactivities are expressed by trigeminal sensory fibres. Cephalalgia (2002) 0.92
The anti-migraine 5-HT(1B/1D) agonist rizatriptan inhibits neurogenic dural vasodilation in anaesthetized guinea-pigs. Br J Pharmacol (2001) 0.92
Depression of nociceptive and other neurones in the brain by iontophoretically applied met-enkephalin. Nature (1976) 0.91
Effects of cholecystokinin and pentagastrin on rat hippocampal neurones maintained in vitro. Neuropeptides (1988) 0.91
Structural analysis of a series of strontium-substituted apatites. Acta Biomater (2008) 0.91
Biocompatibility of glass-ionomer bone cements. J Dent (2006) 0.90
Differences in the effects of ketanserin and GR127935 on 5-HT-receptor mediated responses in rabbit saphenous vein and guinea-pig jugular vein. Eur J Pharmacol (1995) 0.90
Differential effects of 5-HT1B/1D receptor agonists on neurogenic dural plasma extravasation and vasodilation in anaesthetized rats. Neuropharmacology (1997) 0.90
Characterisation of the effects of a non-peptide CGRP receptor antagonist in SK-N-MC cells and isolated human cerebral arteries. Eur J Pharmacol (2001) 0.90
Effects of two truncated forms of human calcitonin-gene related peptide: implications for receptor classification. Eur J Pharmacol (1994) 0.90
The behavioural effects of an N-methylaspartate receptor antagonist following application to the lumbar spinal cord of conscious rats. Neuropharmacology (1984) 0.89
Influence of alkali metal ions on the fracture properties of glass polyalkenoate (ionomer) cements. Biomaterials (1998) 0.88
Analysis of the neurotrophic effects of GPI-1046 on neuron survival and regeneration in culture and in vivo. Neuroscience (1999) 0.88
Microiontophoretic study of depressant amino acids and the specificity of their antagonists. Br J Pharmacol (1973) 0.88
The depolarising action of capsaicin on rat isolated sciatic nerve. Life Sci (1984) 0.88
The kainate/quisqualate receptor antagonist, CNQX, blocks the fast component of spontaneous epileptiform activity in organotypic cultures of rat hippocampus. Neurosci Lett (1988) 0.88
Enantioselective inhibition of the formalin paw late phase by the NK1 receptor antagonist L-733,060 in gerbils. Pain (1996) 0.87
Influence of cement layer thickness on the adhesive bond strength of polyalkenoate cements. Biomaterials (1992) 0.87
Lack of effect of L-687,414 ((+)-cis-4-methyl-HA-966), an NMDA receptor antagonist acting at the glycine site, on cerebral glucose metabolism and cortical neuronal morphology. Br J Pharmacol (1993) 0.87
Pharmacology of tachykinin receptors on neurones in the ventral tegmental area of rat brain slices. Eur J Pharmacol (1995) 0.87
Potentiation of GABA by midazolam and its therapeutic effect against status epilepticus. Folia Psychiatr Neurol Jpn (1983) 0.87
HPLC analysis of components released from dental composites with different resin compositions using different extraction media. J Mater Sci Mater Med (2007) 0.87
Influence of glass composition on the properties of glass polyalkenoate cements. Part I: influence of aluminium to silicon ratio. Biomaterials (1999) 0.87
The effect of casting conditions on the biaxial flexural strength of glass-ceramic materials. Dent Mater (1998) 0.87
Influence of glass composition on the properties of glass polyalkenoate cements. Part IV: influence of fluorine content. Biomaterials (2000) 0.87
Competitive as well as uncompetitive N-methyl-D-aspartate receptor antagonists affect cortical neuronal morphology and cerebral glucose metabolism. Neurochem Res (1993) 0.87
Preliminary investigation of novel bone graft substitutes based on strontium-calcium-zinc-silicate glasses. J Mater Sci Mater Med (2008) 0.86
Development of delta-opioid receptor subtypes and the regulatory role of weaning: radioligand binding, autoradiography and in situ hybridization studies. J Pharmacol Exp Ther (1995) 0.86
GABA-mimetic action of etomidate. Experientia (1978) 0.86
The effects of 5-HT1A, 5-HT1B and 5-HT1D receptor agonists on trigeminal nociceptive neurotransmission in anaesthetized rats. Eur J Pharmacol (1998) 0.86
Highly selective kappa opioid analgesics. Synthesis and structure-activity relationships of novel N-[(2-aminocyclohexyl)aryl]acetamide and N-[(2-aminocyclohexyl)aryloxy]acetamide derivatives. J Med Chem (1988) 0.86